Memantine

Category
nootropic
Routes
Oral (PO)
Half-Life (t½)
PO: 70h
Formula
C12H21N
Molecular Weight
179.3 g/mol
PubChem CID
4054
Aliases
Namenda

Pharmacological Mechanism

Uncompetitive NMDA receptor antagonist with low-to-moderate affinity — preferentially blocks pathologically over-activated channels while sparing physiologic glutamate signaling. FDA-approved for moderate-to-severe Alzheimer's disease.

Half-Life & Elimination Curve (PO: 70h)

100%50%25%12.5%0%0h0×t½70h1×t½5.8d2×t½8.8d3×t½11.7d4×t½14.6d5×t½0×t½ (0h): 100% remaining (~19.9 µg/L)1×t½ (70h): 50% remaining (~9.94 µg/L)2×t½ (5.8d): 25% remaining (~4.97 µg/L)3×t½ (8.8d): 12.5% remaining (~2.48 µg/L)4×t½ (11.7d): 6.3% remaining (~1.24 µg/L)5×t½ (14.6d): 3.1% remaining (~0.621 µg/L)
Plasma (PO)t½ Decay (70h)
  • 0×t½0h100% (19.9 µg/L)
  • 1×t½70h50% (9.94 µg/L)
  • 2×t½5.8d25% (4.97 µg/L)
  • 3×t½8.8d12.5% (2.48 µg/L)
  • 4×t½11.7d6.3% (1.24 µg/L)
  • 5×t½14.6d3.1% (0.621 µg/L)
Elimination t½70h (PO)
Rate Constant (ke)0.0099 h⁻¹
Time to Peak (Tmax)17.1h
Est. Peak (Cmax)19.9 µg/L
Clearance (CL)8.42 L/h
97% Washout (5×t½)14.6d

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References